Trial record 16 of 196 for:    "Lymphedema"

National Lymphatic Disease and Lymphedema Registry

This study is currently recruiting participants. (see Contacts and Locations)
Verified December 2015 by Stanford University
Feinstein Institute for Medical Research
Information provided by (Responsible Party):
Stanley Rockson, Stanford University Identifier:
First received: April 7, 2011
Last updated: December 16, 2015
Last verified: December 2015
The purpose of the National Lymphatic Disease and Lymphedema Registry is to collect health information in order to study the disease classification, natural history, and impact of Lymphatic Disease, Lymphedema and Related Disorders and its treatments and medical outcomes.


Study Type: Observational
Study Design: Observational Model: Case-Only
Official Title: National Lymphatic Disease and Lymphedema Registry

Resource links provided by NLM:

Further study details as provided by Stanford University:

Primary Outcome Measures:
  • prevalence of lymphatic disease [ Time Frame: 15 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • socioeconomic impact of lymphatic disease [ Time Frame: 15 years ] [ Designated as safety issue: No ]
    The data in the registry will be utilized to determine the financial impact of requisite diagnostic and treatment interventions and will be analyzed to consider the relative contribution of third-party payer participation in the cost of care. The financial impact of disease and treatment will be addressed through the financial data entered by registry participants.

Estimated Enrollment: 5000
Study Start Date: March 2009
Estimated Study Completion Date: December 2025
Estimated Primary Completion Date: December 2024 (Final data collection date for primary outcome measure)
Detailed Description:
This project represents the inauguration of a National Patient Registry for Lymphatic Diseases. This project will be completed through an affiliation with the Lymphatic Research Foundation, a non-profit organization whose mission is to promote research and the development of new therapies for patients with lymphatic diseases, including lymphedema. The registry will provide researchers with much-needed clinical data to study the impact of diseases of the lymphatic system, in order to develop improved treatments and find a cure for lymphatic diseases, lymphedema, and related disorders. The establishment of this initiative is a major step forward in research for direct study of groups of patients with lymphatic disease. In the future, this project will be able to be linked with a tissue bank, in which tissue and blood samples derived from patients will be made available for research into human disease states. A national patient registry and tissue/cell bank program paves the way for future clinical trials of experimental drugs and therapies designed to treat lymphatic disease in human subjects.

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Participants (national and international participants) with the presence of lymphatic disease.

Inclusion Criteria:

  • Presence of lymphatic disease

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01336790

Contact: Leslie Roche, RN/BSN (650) 454-7276

United States, California
Stanford University School of Medicine Recruiting
Stanford, California, United States, 94305
Contact: Leslie Roche, RN/BSN    650-454-7276   
Principal Investigator: Stanley G Rockson         
Sponsors and Collaborators
Stanford University
Feinstein Institute for Medical Research
Principal Investigator: Stanley G Rockson Stanford University
  More Information

Additional Information:
Responsible Party: Stanley Rockson, Allan and Tina Neill Professor of Lymphatic Research and Medicine, Stanford University Identifier: NCT01336790     History of Changes
Other Study ID Numbers: SU-04052011-7662  16384 
Study First Received: April 7, 2011
Last Updated: December 16, 2015
Health Authority: United States: Institutional Review Board

Keywords provided by Stanford University:
Lymphatic disease
Protein-losing enteropathy
Vascular Anomalies

Additional relevant MeSH terms:
Lymphatic Diseases
Lymphedema processed this record on May 26, 2016